Biocept to Participate in Two July Investment Conferences
July 19 2021 - 8:00AM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces that Michael
Nall, President and CEO, will participate at the following
investment conferences:
- Brookline Capital Markets Newport Symposium,
“Transformative Biotech – Cancer, Rare Diseases, and Viruses,”
which will feature group and one-on-one investor meetings and panel
discussions with scientific and industry experts. The conference is
being held in Newport, R.I. on July 26.
- A.G.P.’s Virtual MedTech Summer Conference, which will
feature one-on-one investor meetings. The conference is being held
on July 29.
The Biocept Investor Presentation is available here.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept has developed the CNSide™
cerebrospinal fluid (CSF) assay that detects cancer that has
metastasized to the central nervous system. Biocept’s patented
Target Selector™ technology captures and quantitatively analyzes
CSF tumor cells for tumor-associated molecular markers, using
technology first developed for use in blood. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210719005137/en/
Investor Contact: Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100 Media
Contact: Sampson PR Group Andrea Sampson
asampson@sampsonprgroup.com, (562) 304-0301
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Apr 2023 to Apr 2024